Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Objective: To compare the durations of response achieved with adjunctive vagus nerve stimulation (VNS + TAU) vs treatment as usual (TAU) alone in treatment-resistant depression (TRD) over a 5-year period in the TRD registry. Materials and methods: Data from 271 participants on TAU and 328 participants on VNS + TAU were analyzed. Response was defined as ≥50% decrease in baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score at postbaseline visit and was considered retained until the decrease was <40%. MADRS was obtained quarterly in year 1 and biannually thereafter. Time-to-events were estimated using Kaplan–Meier method and compared using log-rank test. HR was estimated using Cox proportion hazard model. Results: In the VNS + TAU arm, 62.5% (205/328) of participants had a first response over 5 years compared with 39.9% (108/271) in TAU. The time to first response was significantly shorter for VNS + TAU than for TAU ( P <0.01). For responders in the first year, median time to relapse from first response was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU vs 7.3 months (Q1=3.1, Q3=17.6) for TAU ( P <0.01). HR=0.6 (95% CI: 0.4, 0.9) revealed a significantly lower chance for relapse in VNS + TAU. Probability of retaining first response for a year was 0.39 (0.27, 0.51) for TAU and 0.47 (0.38, 0.56) for VNS + TAU. Timing of the onset of the response did not impact the durability of the response. Conclusion: VNS therapy added to TAU in severe TRD leads to rapid onset and higher likelihood of response, and a greater durability of the response as compared to TAU alone. Keywords: depressive disorder, treatment-resistant depression, vagus nerve stimulation, longitudinal study, durability of response
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Berry et al found that for VNS + TAU, among participants who achieved response at 24 weeks as per the Montgomery–Åsberg Depression Rating Scale (MADRS), 153 (153/217=71%) had a sustained response at 48 weeks.(9,14) Additionally, of the 104 participants in the VNS + TAU group evaluated at 96 weeks, 70 (70/104=67%) had…”
Method(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“The second challenge focuses on the maintenance of the optimal symptomatic benefit once achieved in the acute treatment phase, that is, the prevention of relapse (a return of the current episode) or recurrence (onset of a new episode).(3,4) The Sequenced Treatment Alternatives to Achieve Remission in Depression (STAR-…”
BackgroundTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Self-citationRush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870 · cited 3×
“Another benchmark by which to evaluate the present results is the Level 4 STAR-D participants all of whom had failed on three prior well-delivered medication treatments.(1) While the acute trial was only 12 weeks in the fourth step, the remission rate was 15% and the response rate was not much greater.”
BackgroundSelf-citation(1997) · PubMed · Cited by 727
Self-citationReport by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 1×
“The second challenge focuses on the maintenance of the optimal symptomatic benefit once achieved in the acute treatment phase, that is, the prevention of relapse (a return of the current episode) or recurrence (onset of a new episode).(3,4) The Sequenced Treatment Alternatives to Achieve Remission in Depression (STAR-…”
BackgroundSelf-citationRush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Giller, C., Nahas, Z., Haines, S., Simpson, R. K., & Goodman, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00304-2 · Cited by 688
Self-citationRush, A. J., Sackeim, H. A., Marangell, L. B., George, M. S., Brannan, S. K., Davis, S. M., Lavori, P., Howland, R., Kling, M. A., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.024 · Cited by 400 · cited 4×
“The standard threshold for defining TRD in the VNS trials is failure of four adequate prior antidepressant treatments, although there is currently not a complete consensus on the required number of medication failures.7 Several reports have found either an earlier or more frequent benefit (in both response or remissio…”
BackgroundResultInfluentialSelf-citationTwo-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes
Nahas, Z., Marangell, L. B., Husain, M. M., Rush, A. J., Sackeim, H. A., Lisanby, S. H., Martinez, J. M., & George, M. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0902 · Cited by 390 · cited 1×
“Similar to prior reports, a substantial proportion (about 50%) of participants who achieved a response maintained that benefit for at least a year after the response began.(9,13,20) In addition, while half of these participants lost this initial response, half achieved a second response in 12 months.”
ResultSelf-citationAaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16010034 · Cited by 381 · cited 12×
“statistical analysis Of the 494 participants in the VNS + TAU arm reported in Aaronson et al, 159 participants who had “crossed over” from VNS treatment in the previously reported flexible dose study were excluded, as most of these subjects had only 1 year of consistent follow-up data and our study aimed to understand…”
BackgroundMethodResultInfluentialSelf-citationGeorge, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372
Self-citationVagus nerve stimulation (VNS) for major depressive episodes: one year outcomes
Marangell, L. B., Rush, A. J., George, M. S., Sackeim, H. A., Johnson, C. R., Husain, M. M., Nahas, Z., & Lisanby, S. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01343-9 · Cited by 290 · cited 1×
“The durability of response in this cohort was somewhat lower than expected from the previous pilot studies and randomized controlled trials.(8,21) Possible explanations include the following: 1) these participants were treated under general clinical conditions not managed by research staff and 2) the sample contained…”
ResultSelf-citationAaronson, S. T., Carpenter, L. L., Conway, C. R., Reimherr, F. W., Lisanby, S. H., Schwartz, T. L., Moreno, F. A., Dunner, D. L., Lesem, M. D., Thompson, P. M., et al. (2013) · Brain Stimulation · doi:10.1016/j.brs.2012.09.013 · Cited by 163 · cited 6×
“statistical analysis Of the 494 participants in the VNS + TAU arm reported in Aaronson et al, 159 participants who had “crossed over” from VNS treatment in the previously reported flexible dose study were excluded, as most of these subjects had only 1 year of consistent follow-up data and our study aimed to understand…”
BackgroundMethodResultInfluentialSelf-citationOlin, B., Berry, Broglio, Bunker, Jayewardene, & Rush (2013) · Medical Devices: Evidence and Research · doi:10.2147/mder.s41017 · Cited by 152 · cited 3×
“Berry et al found that for VNS + TAU, among participants who achieved response at 24 weeks as per the Montgomery–Åsberg Depression Rating Scale (MADRS), 153 (153/217=71%) had a sustained response at 48 weeks.(9,14) Additionally, of the 104 participants in the VNS + TAU group evaluated at 96 weeks, 70 (70/104=67%) had…”
MethodResultSelf-citationDurability of antidepressant response to vagus nerve stimulation (VNS)
Sackeim, H. A., Brannan, S. K., Rush, A. J., George, M. S., Marangell, L. B., & Allen, J. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007425 · Cited by 118 · cited 3×
“Similar to Sackeim et al, the criterion for maintenance of response at the follow-up time points was reduced to an improvement of at least 40% relative to baseline to avoid characterizing a minor decrease (eg, from 51% to 49%) as loss of benefit.(13) A MADRS score drop of 40% constituted a clinically meaningful loss…”
BackgroundMethodResultSelf-citationDefining Remission on the Montgomery-Asberg Depression Rating Scale
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0204 · Cited by 117 · cited 1×
“In addition, the analysis excluded participants who had a baseline MADRS score of 10 as it indicated that they were already remitted from their MDE prior to initiation of treatment; this excluded n=2 from VNS + TAU and n=5 from TAU alone.(19) After the above exclusions and then only including the participants in the…”
MethodConway, C. R., Kumar, A., Xiong, W., Bunker, M., Aaronson, S. T., & Rush, A. J. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12178 · Cited by 92
Self-citationOlin, B., Jayewardene, A. K., Bunker, M., & Moreno, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048002 · Cited by 63 · cited 1×
“The eligibility criteria for the TRD registry are detailed elsewhere.(6,15) Briefly, participants had to be 18 years of age or older and experiencing a major depressive episode (MDE) of 2 years or longer in duration (either unipolar or bipolar depression) or have a history of at least three MDEs including the current…”
BackgroundSelf-citationRush, A. J., Marangell, L. B., Sackeim, H. A., George, M. S., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Rittberg, B. R., Burke, W. J., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.025 · Cited by 44
Self-citation
Research works printed but not linked: 1
- [7]AHRQ Technology Assessment Program: Definition of Treatment-Resistant Depression in the Medicare Population. Project ID: PSYT0816 Agency for Healthcare Research and Quality. US Department of Health and Human Services 2018 Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id105TA.pdf Accessed April 18, 2018 30260611
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationBottomley, J. M., LeReun, C., Diamantopoulos, A., Mitchell, S., & Gaynes, B. N. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152156 · Cited by 138
Vagus Nerve Stimulation in Rodent Models: An Overview of Technical Considerations
Noller, C. M., Levine, Y. A., Urakov, T. M., Aronson, J. P., & Nash, M. S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00911 · Cited by 70
Neuromodulation Strategies for the Treatment of Depression
Conroy, S. K., & Holtzheimer, P. E. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21101034 · Cited by 68
Metadata
- Authors
- Kumar, A., Bunker, M. T., Aaronson, S. T., Conway, C. R., Rothschild, A. J., Mordenti, G., & Rush, A. J.
- Affiliations
- LivaNova (United States) (US)
- Washington University in St. Louis (US)
- Sheppard and Enoch Pratt Hospital (US)
- University of Massachusetts Chan Medical School (US)
- National University of Singapore (SG)
- Corresponding author
- Kumar, Arun
- ORCID
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-02
- Volume
- Volume 15
- Pages
- 457-468
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC6387594
- OpenAlex
- W2912354242
- Cited by
- 44
- References
- 23
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 2
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, other-oa)
- eScholarship@UMassChan (submittedVersion, cc-by-nc)
- National University of Singapore (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Stanley Medical Research Institute
- Foundation for Barnes-Jewish Hospital
- University of Texas Southwestern Medical Center
- Sunovion
- LivaNova
- Neurocrine Biosciences
- Sage Therapeutics
- Assurex Health
- NeoSync
- National Institutes of Health
- Allergan
- National Institute of Mental Health
- Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
- Topics
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- vagus nerve stimulation, treatment-resistant depression, adjunctive therapy, durability of response, relapse, time to response, usual care, severe depression, longitudinal outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.